Identity, dose, and route of virus challenge known.
Control for various clinical parameters that are virtually impossible to control in humans (time of infection, duration of ART etc).
Comprehensive cellular and anatomic characterization of both active and persistent reservoirs (including elective necropsy).
Pilot trials of in vivo eradication conducted in a timely and controlled fashion; treatment interruption is possible.
Testing of “risky” interventions (i.e., cell depletion experiments, stem cell-based interventions etc).
|